Skip to search.
New User?
Register
Sign In
Help
Make Y! My Homepage
Notifications
Help
Mail
My Y!
Yahoo!
Yahoo! Canada Finance
Search
Search Web
HOME
PHOTOS
VIDEO
Daily Ticker
Money Minute
NEWS
Canada
Retail
Technology
World
PERSONAL FINANCE
Careers
Investing & Planning
Real Estate
Retirement
Saving & Spending
TFSA
BLOGS
Balance Sheet
Dashboard
Insight
Pay Day
INVESTING
Currency Converter
Currencies
Markets
Bonds
Commodities
Canada Indices
US Indices
World Indices
Price Gainers
Price Losers
Providers
MY PORTFOLIO
Sign in to access My Portfolios
THE GOOD LIFE
Automobiles
Homes & Design
Travel & Hotels
Wealth & Luxury
Search for share prices
Search for share prices
Sun May 26, 2013 5:08AM EDT - Canadian Markets closed
TSX
0.07%
TSX Ventures
0.00%
More On ACOR
Quotes
Summary
Order Book
Options
Historical Prices
Charts
Interactive
Basic Chart
Basic Tech. Analysis
News & Info
Headlines
Company Events
Market Pulse
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Components
Analyst Coverage
Analyst Opinion
Analyst Estimates
Ownership
Major Holders
Insider Transactions
Insider Roster
Financials
Income Statement
Balance Sheet
Cash Flow
Acorda Therapeutics, Inc. (ACOR)
-
NasdaqGS
32.67
0.44
(1.37%)
May 24, 4:00PM EDT
Add to Portfolio
Headlines
Get Headlines for:
Thursday, 23 May, 2013
Alkermes Earnings Beat Estimates, But Outlook Unclear
at Investor's Business Daily
(Thu May 23)
Alkermes posts 4Q profit as royalty payments rise
AP
(Thu May 23)
Wednesday, 22 May, 2013
Alkermes Earnings Seen Rising, But Sales Uncertain
at Investor's Business Daily
(Wed May 22)
Additional Patent for Acorda's Ampyra
Zacks
(Wed May 22)
Tuesday, 21 May, 2013
CORRECTING and REPLACING Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis
Business Wire
(Tue May 21)
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online
(Tue May 21)
Monday, 20 May, 2013
4 Healthcare Stock Stories Prescribed For Investors
at Wall St. Cheat Sheet
(Mon May 20)
Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths
Business Wire
(Mon May 20)
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online
(Mon May 20)
Friday, 17 May, 2013
ACORDA THERAPEUTICS INC Financials
EDGAR Online Financials
(Fri May 17)
Acorda Therapeutics’ Legal Department Recognized on Best Legal Departments List by Corporate Counsel Magazine
Business Wire
(Fri May 17)
Wednesday, 15 May, 2013
Acorda Therapeutics to Present at the UBS Global Healthcare Conference
Business Wire
(Wed May 15)
Friday, 10 May, 2013
ACORDA THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online
(Fri May 10)
Thursday, 9 May, 2013
Acorda says data support initiation of current dalfampridine development program
theflyonthewall.com
(Thu May 9)
Acorda Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Business Wire
(Thu May 9)
Acorda Therapeutics Announces Data Showing Dalfampridine Improves Motor Function in Preclinical Model of Post-Stroke Deficits Published in Stroke
Business Wire
(Thu May 9)
ACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online
(Thu May 9)
Monday, 6 May, 2013
Acorda Incurs Loss, Maintains Guidance
Zacks
(Mon May 6)
Acorda Therapeutics Recognized as One of the Best Places to Work in New York State for Third Consecutive Year
Business Wire
(Mon May 6)
Wednesday, 6 March, 2013
Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN Annual Meeting
Business Wire
(Wed Mar 6)
Older Headlines
View headlines from:
Tuesday, 5 March, 2013
Tuesday, 26 February, 2013
Tuesday, 19 February, 2013
Tuesday, 12 February, 2013
Tuesday, 5 February, 2013
Tuesday, 29 January, 2013
Tuesday, 22 January, 2013
Tuesday, 15 January, 2013
Tuesday, 8 January, 2013
Tuesday, 1 January, 2013
1184550158